- Home
- PBPB vs ADCT Comparison
PBPB vs ADCT Comparison
Compare PBPB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- ADCT
- Stock Information
- Founded
- PBPB 1977
- ADCT 2011
- Country
- PBPB United States
- ADCT Switzerland
- Employees
- PBPB N/A
- ADCT N/A
- Industry
- PBPB Restaurants
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- ADCT Health Care
- Exchange
- PBPB Nasdaq
- ADCT Nasdaq
- Market Cap
- PBPB 313.6M
- ADCT 224.3M
- IPO Year
- PBPB 2013
- ADCT 2020
- Fundamental
- Price
- PBPB $9.89
- ADCT $3.20
- Analyst Decision
- PBPB Strong Buy
- ADCT Strong Buy
- Analyst Count
- PBPB 3
- ADCT 5
- Target Price
- PBPB $15.67
- ADCT $7.33
- AVG Volume (30 Days)
- PBPB 123.7K
- ADCT 986.3K
- Earning Date
- PBPB 11-07-2024
- ADCT 11-07-2024
- Dividend Yield
- PBPB N/A
- ADCT N/A
- EPS Growth
- PBPB 641.95
- ADCT N/A
- EPS
- PBPB 1.25
- ADCT N/A
- Revenue
- PBPB $471,719,000.00
- ADCT $70,717,000.00
- Revenue This Year
- PBPB N/A
- ADCT $6.38
- Revenue Next Year
- PBPB $3.71
- ADCT $11.73
- P/E Ratio
- PBPB $7.93
- ADCT N/A
- Revenue Growth
- PBPB N/A
- ADCT N/A
- 52 Week Low
- PBPB $6.28
- ADCT $0.98
- 52 Week High
- PBPB $14.36
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- PBPB 54.04
- ADCT 64.22
- Support Level
- PBPB $9.96
- ADCT $1.80
- Resistance Level
- PBPB $10.64
- ADCT $2.38
- Average True Range (ATR)
- PBPB 0.30
- ADCT 0.28
- MACD
- PBPB -0.09
- ADCT 0.12
- Stochastic Oscillator
- PBPB 32.43
- ADCT 88.05
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.